AestheticsFeatured Articles

Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement

By August 25, 2020No Comments

Featured Article

Featured Article

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Read more

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Michelle E. Walters MD, Delphine J. Lee MD PhD, Paul S. Yamauchi MD PhD

Psoriasis is a chronic skin condition with a negative impact on patient quality of life. The National Psoriasis Foundation states that an acceptable response to psoriasis treatment is at least a 75% reduction in body surface area (BSA) at 3 months after initiation of treatment.

This reduction in BSA has been associated with improvement in quality of life, with clearance rates of clear to almost clear leading to an even greater improvement in quality of life.2,3 To date, there have been no studies examining the relationship between improvement in quality of life following a reduction in BSA, and the increased utilization of cosmetic procedures. Here, we examine the relationship between quality of life and the use of various cosmetic procedures in patients treated for psoriasis with systemic and biologic therapies who achieved at least 75% reduction in BSA.

This was a retrospective study assessing quality of life and the use of cosmetic procedures in psoriasis patients after attaining a75% or greater reduction of the body surface area with biologic agents only, systemic agents only, or a combination of both. This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki. All patients provided informed consent.

Read Full Article Now
Article Cited in this Post

You May Also Like

Journal of Drugs in Dermatology JDD Article about Enhancing Patient Privacy in Dermatology: Best Practices for Image Organization and Security

Enhancing Patient Privacy in Dermatology: Best Practices for Image Organization and Security

| Derm Community, Featured Articles, Latest News, Social and Technology | No Comments
Practical imaging security for dermatologists: encryption, secure storage, metadata hygiene and device protocols In this Letter to the Editor published in the February issue of the Journal of Drugs in…
Journal of Drugs in Dermatology JDD featuring Author Spotlight: Aaron S. Farberg MD FAAD

Author Spotlight: Aaron S. Farberg MD FAAD

| Author Spotlight, Featured Articles, Latest News, Medical Derm | No Comments
Check Out JDD Corner’s Latest Author Spotlight Our current Author Spotlight features Aaron S. Farberg MD FAAD, one of the co-authors of “Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists:…
Journal of Drugs in Dermatology JDD Article about A Systematic Evaluation of Monkeypox Public Health Educational Resources

A Systematic Evaluation of Mpox Public Health Educational Resources

| Featured Articles, Global Health, Latest News | No Comments
Public health messaging misses the mark on Monkeypox and HIV A cross‑jurisdiction survey of publicly available Monkeypox and HIV materials from state, large metropolitan and select non‑metro U.S. health departments…

Leave a Reply